Dr. Paul and Mrs. Jean Corcoran started 'Dentistry from the Heart' eight years ago as a result of his cumulative experience seeing patients in the ER with extreme dental needs for several decades. Corcoran felt compelled to do something about it, and his work has been recognized by the community: Vail Valley magazine published a profile on Corcoran and Dentistry from the Heart in its October issue.
“We open the office to whoever wants to come in. We do one procedure per person, a cleaning or a filling or tooth extraction. In a lot of ways that’s the best day of the year,” said Corcoran in the Vail Valley issue.
Corcoran has extended his generosity to the University of Maryland School of Dentistry as well. Paul and Jean have established the Dr. and Mrs. Paul Corcoran and Dr. and Mrs. Jeff Cooper Scholarship Endowment Fund to provide support to UMSOD students who are facing academic or personal challenges. The fund is a fitting tribute to Dr. Cooper’s selflessness and generosity, as well as testament to the bond the two have maintained over the years.
In October 2020, Robert K. Ernst, PhD, was announced as the inaugural Dr. Paul and Mrs. Jean Corcoran Endowed Professor. Created to recognize and support a well-established research team that will provide a positive economic impact on Maryland commerce, the endowment was funded through the generosity of Paul Corcoran, DDS ’75, and Jean Corcoran in partnership with the Maryland E-Novation Initiative Fund. Ernst, professor and vice chair, Department of Microbial Pathogenesis, has received more than $14 million in research funding since arriving at UMSOD in 2018 and is co-founder of the startup Pataigin LLC.
“Endowed professorships empower the school to recruit and retain outstanding faculty members as well as support in perpetuity their work as educators, scholars, researchers, and clinicians,” said Mark A. Reynolds, DDS ’86, PhD, MA, dean of UMSOD. “The philanthropic establishment of endowments by alumni and friends helps foster enduring academic excellence.”
Contract, NIH/NIAID (PI): Adjuvant development of the TLR4 ligand BECC470s (2023-2028) Develop the adjuvant potential of BECC470s through IND-enabling studies.
R21, NIH/NIAID (MPI): Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress (2023-2025) Use spatial metabolomics and lipid A mapping to correlate the relationship between Pa lipid A and the host lung response.
R43, NIH/NIAID (subcontract): Rapid Microbial ID Direct from Specimen (2023-2024) Develop a prototype clinical assay to evaluate clinical specimens for identification of pathogens using MS without ex vivo growth.
R01, NIH/NIAID (Co-I): Structural determinants of activity and mechanism of cationic peptide antibiotic activity against colistin-resistant bacteria (2023-2028) Determine how resistance patterns of levels of colistin resistance correlate with the quantities of amino-containing moieties in lipid A.
Cystic Fibrosis Foundation (PI): Characterization of airway responses to adaptive P. aeruginosa lipid A structural variants in CF (2023-2025) Determine the prevalence of specific lipid A biosynthetic enzyme alterations in a diverse cohort of clinical Pa isolates and evaluate the host response.
R01, NIH/NIAID (Co-I): A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa (2022-2027) Develop a prophylactic vaccine using the BECC adjuvant system to prevent initial colonization by P. aeruginosa.
R01, NIH/NIAID (Co-I): Repurposing Gram-Positive Antibiotics for Gram-negative Bacteria using Antibiotic Adjuvants (2022-2027) Elucidate specific changes in the structure of lipid A A. baumannii to determine the effect of the novel compounds to specifically downregulate LPS alterations.
DOD, (Co-I): Pain and the Immune System: A Novel Therapeutic Approach (2021-2025) Examine altering the host innate immune response in treating chronic pain.
R21, NIH/NIA (Co-I): Preventing Alzheimer's Disease with Designer Lipids (2021-2023) Determine the compatibility of a probiotic strain with long-term gut colonization in a mouse model of Alzheimer’s disease.
R01, NIH/NIDCR (Co-I): Novel Target Identification for Treatment of Chronic Overlapping Pain Using Multimodal Brain Imaging (2020-2024) Determine novel biomarkers and therapeutic targets for chronic overlapping pain conditions.
R01, NIH/NIAID (MPI): MS diagnostic bacterial identification library (2020-2025) Establish a rapid, small scale extraction procedure for lipids isolated from bacterial and fungal pathogens.
DOD, (PI): Novel Live Vaccines with Modified Lipid A for the Prevention of Shigella Diarrheal Disease (2019-2023 NCE) Engineer and evaluate live attenuated Shigella subspecies vaccines with alterations in lipid A molecule for use as a live oral vaccine.
Contract, NIH/NIAID (PI): Adjuvant development of the TLR4 ligand, BECC438 (2018-2023 NCE) Develop the adjuvant potential of BECC438 through IND-enabling studies.
R01, NIH/NIAID (Co-I): Development of Antibiotic Adjuvants for Gram-Negative Bacteria (2018-2023 NCE) Elucidate changes in the structure of lipid A to novel small molecule antimicrobial.
University System of Maryland – Regents Award – Excellence in Research
Dr. Paul and Mrs. Jean Corcoran Endowed Professorship
Entrepreneur of the Year, University of Maryland – Baltimore
Dr. Mark E Shirtliff PhD Student Mentor Award, University of Maryland - Baltimore
Researcher of the Year, University of Maryland – Baltimore
Maryland Department of Commerce Life Award –UMB-JHU Pataigin – Lipid-based microbial diagnostic platform
Maryland-John Hopkins Alliance Ventures award – Anti-sepsis therapeutics
Maryland-John Hopkins Alliance Ventures award – Lipid-based bacterial diagnostic platform
Philip and Helen Fialkow Scholar Award, Outstanding Assistant Professor, School of Medicine, University of Washington
Copyright © 2024 Ernst Laboratory - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.